Literature DB >> 3024755

Loss of interleukin-2 requirement for the generation of T colonies defines an early event of human T-lymphotropic virus type I infection.

M Duc Dodon, L Gazzolo.   

Abstract

Accessory cells and/or soluble factors, together with interleukin 2 (IL2), are required for the proliferation and differentiation of phytohemagglutinin (PHA)-activated T lymphocytes. Human T-lymphotropic virus, type I (HTLV-I), a human retrovirus isolated from patients with adult T cell leukemia, can transform T cells in vitro. We investigated the role of HTLV-I-transformed T cell lines as accessory cells in promoting the growth of T colony-forming cells. We found that T cells isolated by E rosetting and then activated with PHA, when seeded with as few as 5 X 10(3) irradiated HTLV-I-producing cells, could generate colonies in the absence of IL2. We analyzed further the effects of HTLV-I virions on T colony formation. Infection of T cells with semipurified HTLV-I viral particles promoted colony formation, in the absence of IL2, of accessory cells or soluble factors. The same results were obtained either with monocyte-depleted T lymphocytes, or with T4 or T8 lymphocytes. Furthermore, T lymphocytes in the presence of heat-inactivated HTLV-I (devoid of replicative potential) could form colonies independently of IL2. Finally, experiments with sera positive for HTLV-I antibodies (to abolish binding of viral particles to cellular receptors) indicated that HTLV-I promoted IL2-independent colony formation, only by "touching" T colony-forming cells. These results taken together demonstrate that the loss of the exogenous IL2 (and other growth-helping factors) requirement defines an early event of HTLV-I infection. The results also suggest that viral attachment to T cells possibly supplies an accessory function triggering autocrine secretion of IL2 by these cells.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3024755

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  8 in total

1.  Effect of human T-cell leukemia virus type I tax protein on activation of the human vimentin gene.

Authors:  A Lilienbaum; M Duc Dodon; C Alexandre; L Gazzolo; D Paulin
Journal:  J Virol       Date:  1990-01       Impact factor: 5.103

2.  Protein kinase A-dependent binding of a nuclear factor to the 21-base-pair repeat of the human T-cell leukemia virus type I long terminal repeat.

Authors:  H T Poteat; F Y Chen; P Kadison; J G Sodroski; W A Haseltine
Journal:  J Virol       Date:  1990-03       Impact factor: 5.103

3.  Purification and characterization of multiple nuclear factors that bind to the TAX-inducible enhancer within the human T-cell leukemia virus type 1 long terminal repeat.

Authors:  T H Tan; M Horikoshi; R G Roeder
Journal:  Mol Cell Biol       Date:  1989-04       Impact factor: 4.272

4.  Peripheral T-lymphocyte activation by human T-cell leukemia virus type I interferes with the CD2 but not with the CD3/TCR pathway.

Authors:  M D Dodon; A Bernard; L Gazzolo
Journal:  J Virol       Date:  1989-12       Impact factor: 5.103

Review 5.  Mechanisms of T-cell activation by human T-cell lymphotropic virus type I.

Authors:  P Höllsberg
Journal:  Microbiol Mol Biol Rev       Date:  1999-06       Impact factor: 11.056

6.  Human T-cell leukemia virus type I-induced proliferation of human immature CD2+CD3- thymocytes.

Authors:  V Maguer; H Cassé-Ripoll; L Gazzolo; M D Dodon
Journal:  J Virol       Date:  1993-09       Impact factor: 5.103

7.  Human T-cell leukemia virus type I infection of CD4+ or CD8+ cytotoxic T-cell clones results in immortalization with retention of antigen specificity.

Authors:  D V Faller; M A Crimmins; S J Mentzer
Journal:  J Virol       Date:  1988-08       Impact factor: 5.103

8.  Abnormal in vitro proliferation and differentiation of T cell colony-forming cells in patients with tropical spastic paraparesis/human T lymphocyte virus type I (HTLV-I)-associated myeloencephalopathy and healthy HTLV-I carriers.

Authors:  Y Lunardi-Iskandar; A Gessain; V H Lam; R C Gallo
Journal:  J Exp Med       Date:  1993-03-01       Impact factor: 14.307

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.